SCHEMBL16615362

SCHEMBL16615362

COc1cc(N2CCC(N(C)C)CC2)ccc1Nc1cc2c(nn1)NCCN2Cc1c(Cl)ccc(F)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 13/20 0.40
EGFR P00533 4/20 0.40
FGFR1 P11362 3/20 0.40
ROS1 P08922 2/20 0.40
INSR P06213 2/20 0.40
IGF1R P08069 2/20 0.40
AURKA O14965 1/20 0.40
EML4 Q9HC35 1/20 0.40
PLK1 P53350 1/20 0.39
FGFR3 P22607 2/20 0.37
JAK2 O60674 2/20 0.37
SRC P12931 2/20 0.37
PLK4 O00444 1/20 0.37
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37
ABL1 P00519 1/20 0.37
LCK P06239 1/20 0.37
CSF1R P07333 1/20 0.37
RET P07949 1/20 0.37
MET P08581 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19069468 0.96 ALK (0.40) ALKEGFRFGFR1ROS1INSR
SCHEMBL16615271 0.91 ALK (0.39) ALKFGFR1ROS1INSRIGF1R
SCHEMBL17969758 0.91 EGFR (0.39) ALKEGFRFGFR1ROS1INSR
SCHEMBL17918707 0.88 ALK (0.41) ALKEGFRFGFR1ROS1INSR
SCHEMBL17969787 0.86 ALK (0.41) ALKEGFRFGFR1ROS1FGFR3
SCHEMBL17918767 0.84 ALK (0.44) ALKEGFRFGFR1ROS1INSR
SCHEMBL17918794 0.82 ALK (0.41) ALKEGFRFGFR1ROS1INSR
SCHEMBL16615294 0.81 ALK (0.44) ALKFGFR1ROS1IGF1RAURKA
SCHEMBL16615280 0.79 LRRK2 (0.45) ALK
SCHEMBL17969778 0.79 LRRK2 (0.47) ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9695182-B2 Chemical compounds (derivatives) and their application for the treatment of oncological diseases LIMITED LIABILITY COMPANY “NATIONAL PHARMACEUTICAL TECHNOLOGIES” (RU) 2017-07-04 US disclosed
EP-3050884-A1 NOVEL CHEMICAL COMPOUNDS (VARIANTS) AND THE USE THEREOF TO TREAT ONCOLOGICAL DISEASES Limited Liability Company "National Pharmaceutical (RU) 2016-08-03 EP disclosed
US-20160200729-A1 NEW CHEMICAL COMPOUNDS (DERIVATIVES) AND THEIR APPLICATION FOR THE TREATMENT OF ONCOLOGICAL DISEASES LIMITED LIABILITY COMPANY (RU) 2016-07-14 US disclosed
WO-2015047133-A1 NOVEL CHEMICAL COMPOUNDS (VARIANTS) AND THE USE THEREOF TO TREAT ONCOLOGICAL DISEASES ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ОТЕЧЕСТВЕННЫЕ ФАРМАЦЕВТИЧЕСКИЕ ТЕХНОЛОГИИ" 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160200729-A1 NEW CHEMICAL COMPOUNDS (DERIVATIVES) AND THEIR APPLICATION FOR THE TREATMENT OF ONCOLOGICAL DISEASES BRAF, CNKSR1, RAF1 ALK 1031/4885EGFR 682/4885FGFR1 988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.